Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Ryan, John T; Nakayama, Masao; Gleeson, Ian; Mannion, Liam; Geso, Moshi; Kelly, Jennifer; Ng, Sweet Ping; Hardcastle, Nicholas

doi:10.1186/s13014-022-02146-8

Table 4 Recurrence outcomes

From: Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Study name	Citations	Functional imaging agent	Intervention aim							Treatment
Study name	Citations	Functional imaging agent	Improve standard RTtarget delineation	Facilitate doseescalation	Facilitate organ at risk sparing	Map recurrence & RT treated volumes	Map functional volumes& RT planning volumes	Map treated functionalvolumes & survival	Map radiomic features& RT volumes	Standard treatment	Standard targetvolumes changed	Dose escalation
Niyazi	[32, 33]	F18-FET PET				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Piroth	[34,35,36,37]	F18-FET PET		\(\checkmark\)		\(\checkmark\)		\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
Lundemann	[42,43,44]	F18-FET PET	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)		\(\checkmark\)		\(\checkmark\)
Harat	[47]	F18-FET PET				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Hayes	[48]	F18-FET PET	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)				\(\checkmark\)
Fleischmann	[49]	F18-FET PET				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Vigil	[52, 53]	C11-MET PET		\(\checkmark\)		\(\checkmark\)	\(\checkmark\)	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)
Hirata	[54, 55]	C11 MET & F18-FDG PET				\(\checkmark\)	\(\checkmark\)	\(\checkmark\)		\(\checkmark\)
Christensen	[56, 57]	C11-AMT PET				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Kosztyla	[58]	F18-FDOPA PET				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Wahl	[65]	DW & DCE MRI				\(\checkmark\)	\(\checkmark\)	\(\checkmark\)		\(\checkmark\)
Berberat	[69]	DTI MRI				\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Peeken	[73]	DTI MRI				\(\checkmark\)	\(\checkmark\)		\(\checkmark\)	\(\checkmark\)
Morin	[74]	DW MRI	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Anwar	[75]	DWI & PWI MRI, & MRSI				\(\checkmark\)			\(\checkmark\)	\(\checkmark\)

Study name	Max dose			Dose fractionation (Gy/fractions)	Recurrence pattern						Recurrence comments
Study name	BED\(_{2}\) (Gy)	BED\(_{10}\) (Gy)	EQD\(_2\) (Gy)		Central-S %	Central-S+F %	Marginal-S %	Marginal-S+F %	Distal-S %	Distal-S+F %
Niyazi	120	72	60	60/30	50	50	25	33.3	25	16.7
Piroth	158.4	89.3	74.4	72/30		78		16.6		5.3
Lundemann	120	72	60	60/30		82		12		6
Harat	120	72	60	60/30		69		8		23	Recurrences were significantly more frequent in the areas with marginal therapeutic dose (57-59.9 Gy)
Hayes	120	72	60	60/30							High agreeance between T2 FLAIR and FET activity and recurrence location
Fleischmann	120	72	60	60/30	83.3	88.9	11.1	5.6	5.6	5.6
Vigil	Not reported but escalated										MRI recurrence volume matched the highest uptake area of GTV MET in 30/40 patients
Hirata	120	72	60	60/30							Decoupling score volume was predictive of recurrence
Christensen	120	72	60	60/30	58	72	14	14	28	14
Kosztyla	120	72	60	60/30	72	86	14	0	14	14
Wahl	120	72	60	60/30							Functional and anatomical combined volume was twice as likely to include recurrence than either independent volume alone
Berberat	120	72	60	60/30	0-50	0-50	0-50	0-50	50	50
Peeken	120	72	60	60/30		100
Morin	120	72	60	60/30	80	100	0-20	0	0-20	0
Anwar	120	72	60	60/30	0-77		0-77		23		25% of recurrence voxels resided outside the traditional 2 cm treatment boundary. 75% of voxels within the 2 cm treatment margin did not progress

BED\(_2\) Biological effective dose (alpha/beta = 2), BED\(_{10}\) Biological effective dose (alpha/beta = 10), EQD\(_2\) Equivalent dose in 2 Gy (alpha/beta = 10), S Standard imaging, S + F = Standard and functional imaging combined

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us